Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Sci Rep ; 11(1): 6989, 2021 03 26.
Article in English | MEDLINE | ID: mdl-33772064

ABSTRACT

Diquafosol tetrasodium (DQS), a purinergic P2Y2 receptor agonist, stimulates secretion of both water and mucins from the conjunctiva into tears. Hence, DQS-containing eye drops have been approved as a therapeutic option for dry eye disease in some Asian countries, including Japan. Recent clinical reports state that instilling DQS-containing eye drops significantly increases the lipid layer thickness in tears. Therefore, we examined this compound's direct actions on holocrine lipid-secreting meibomian gland cells and their function. Isolated meibomian gland cells (meibocytes) were procured from rabbits and cultivated in serum-free culture medium. Differentiated meibocytes with pioglitazone were used for the subsequent experiments. Intracellular Ca2+ signalling of the cells was dramatically elevated with DQS addition in a dose-dependent manner. This DQS-induced elevation was almost completely cancelled by the coexistence of the selective P2Y2 receptor antagonist AR-C118925XX. DQS treatment also facilitated total cholesterol (TC) release from cells into the medium. This effect of DQS on TC was suppressed significantly by the intracellular Ca2+ chelator BAPTA-AM as well as by AR-C118925XX. DNA fragmentation analysis revealed that DQS may have enhanced the apoptotic DNA fragmentation caused spontaneously by cells. Thus, DQS could stimulate meibocytes to release lipids through the P2Y2 receptor and possibly facilitate holocrine cell maturation.


Subject(s)
Cholesterol/metabolism , Meibomian Glands/metabolism , Ophthalmic Solutions/pharmacology , Polyphosphates/pharmacology , Receptors, Purinergic P2Y2/metabolism , Uracil Nucleotides/pharmacology , Animals , Cells, Cultured , Dry Eye Syndromes/pathology , Meibomian Glands/cytology , Purinergic P2Y Receptor Agonists/pharmacology , RNA, Messenger/genetics , Rabbits , Receptors, Purinergic P2Y2/genetics , Tears/chemistry
2.
Sci Rep ; 10(1): 22343, 2020 12 18.
Article in English | MEDLINE | ID: mdl-33339841

ABSTRACT

Despite efficient and specific in vitro knockdown, more reliable and convenient methods for in vivo knockdown of target genes remain to be developed particularly for retinal research. Using commercially available and chemically modified siRNA so-called Accell siRNA, we established a novel in vivo gene silencing approach in the rat retina. siRNA designed for knockdown of the house keeping gene Gapdh or four retinal cell type-specific genes (Nefl, Pvalb, Rho and Opn1sw) was injected into the vitreous body, and their retinal mRNA levels were quantified using real-time PCR. Intravitreal injection of siRNA for Gapdh resulted in approximately 40-70% reduction in its retinal mRNA levels, which lasted throughout a 9-day study period. Furthermore, all the selected retinal specific genes were efficiently down-regulated by 60-90% following intravitreal injection, suggesting injected siRNA penetrated into major retinal cell types. These findings were consistent with uniform distribution of a fluorescence-labeled siRNA injected into the vitreous body. Interestingly, gene silencing of Grin1, a core subunit of NMDA receptor, was accompanied by significant prevention from NMDA-induced retinal ganglion cell death. Thus, we provide single intravitreal injection of Accell siRNA as a versatile technique for robust and sustainable in vivo retinal gene silencing to characterize their biological functions under physiological and pathophysiological conditions.


Subject(s)
Gene Silencing/drug effects , Genetic Therapy , RNA, Small Interfering/pharmacology , Receptors, N-Methyl-D-Aspartate/genetics , Retinal Diseases/therapy , Animals , Genes, Essential/genetics , Humans , Intravitreal Injections , RNA, Double-Stranded/genetics , RNA, Double-Stranded/pharmacology , Rats , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Retina/pathology , Retinal Diseases/genetics , Retinal Diseases/pathology , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/pathology , Vitreous Body/drug effects
3.
Mar Drugs ; 18(9)2020 Sep 18.
Article in English | MEDLINE | ID: mdl-32962073

ABSTRACT

Several antitumour drugs have been isolated from natural products and many clinical trials are underway to evaluate their potential. There have been numerous reports about the antitumour effects of astaxanthin against several tumours but no studies into its effects against glioblastoma. Astaxanthin is a red pigment found in crustaceans and fish and is also synthesized in Haematococcus pluvialis; adonixanthin is an intermediate product of astaxanthin. It is known that both astaxanthin and adonixanthin possess radical scavenging activity and can confer a protective effect on several damages. In this study, we clarified the antitumour effects of astaxanthin and adonixanthin using glioblastoma models. Specifically, astaxanthin and adonixanthin showed an ability to suppress cell proliferation and migration in three types of glioblastoma cells. Furthermore, these compounds were confirmed to transfer to the brain in a murine model. In the murine orthotopic glioblastoma model, glioblastoma progression was suppressed by the oral administration of astaxanthin and adonixanthin at 10 and 30 mg/kg, respectively, for 10 days. These results suggest that both astaxanthin and adonixanthin have potential as treatments for glioblastoma.


Subject(s)
Brain Neoplasms/drug therapy , Carotenoids/pharmacology , Glioblastoma/drug therapy , Administration, Oral , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Carotenoids/administration & dosage , Cell Line, Tumor , Disease Progression , Glioblastoma/pathology , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Xanthophylls/administration & dosage , Xanthophylls/pharmacology
4.
IEEE Trans Neural Syst Rehabil Eng ; 22(2): 352-62, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24608689

ABSTRACT

Although joint biomechanics and whole-body energetics are well documented for human walking, the underlying mechanisms that govern individual muscle-tendon behaviors are not fully understood. Here, we present a computational model of human walking that unifies muscle and joint biomechanics with whole-body metabolism for level-ground walking at self-selected speed. In the model, muscle-tendon units that dorsiflex the ankle, and flex and extend the knee, are assumed to act as linear springs upon neural activation; each muscle-tendon is modeled as a tendon spring in series with an isometric force source. To provide the mechanical power lost in step-to-step gait transitions, a Hill-type soleus muscle is modeled to actively plantar flex the ankle using muscle state and force as reflex feedback signals. Finally, to stabilize the trunk during stance, and to protract and retract each leg throughout the swing phase, two mono-articular Hill-type muscles actuate the model's hip joint. Following a forward dynamics optimization procedure, the walking model is shown to predict muscle and joint biomechanics, as well as whole-body metabolism, supporting the idea that the preponderance of leg muscles operate isometrically, affording the relatively high metabolic walking economy of humans.


Subject(s)
Muscle, Skeletal/physiology , Tendons/physiology , Walking/physiology , Algorithms , Ankle/physiology , Biomechanical Phenomena , Computer Simulation , Energy Transfer/physiology , Foot/physiology , Hip Joint/physiology , Humans , Isometric Contraction/physiology , Joints/physiology , Kinetics , Leg/physiology , Locomotion/physiology , Muscle, Skeletal/innervation , Muscle, Skeletal/metabolism , Oxygen Consumption/physiology , Posture , Reflex/physiology , Thigh/physiology , Torque
5.
Philos Trans R Soc Lond B Biol Sci ; 366(1570): 1621-31, 2011 May 27.
Article in English | MEDLINE | ID: mdl-21502131

ABSTRACT

Control schemes for powered ankle-foot prostheses would benefit greatly from a means to make them inherently adaptive to different walking speeds. Towards this goal, one may attempt to emulate the intact human ankle, as it is capable of seamless adaptation. Human locomotion is governed by the interplay among legged dynamics, morphology and neural control including spinal reflexes. It has been suggested that reflexes contribute to the changes in ankle joint dynamics that correspond to walking at different speeds. Here, we use a data-driven muscle-tendon model that produces estimates of the activation, force, length and velocity of the major muscles spanning the ankle to derive local feedback loops that may be critical in the control of those muscles during walking. This purely reflexive approach ignores sources of non-reflexive neural drive and does not necessarily reflect the biological control scheme, yet can still closely reproduce the muscle dynamics estimated from biological data. The resulting neuromuscular model was applied to control a powered ankle-foot prosthesis and tested by an amputee walking at three speeds. The controller produced speed-adaptive behaviour; net ankle work increased with walking speed, highlighting the benefits of applying neuromuscular principles in the control of adaptive prosthetic limbs.


Subject(s)
Ankle Joint/physiology , Artificial Limbs , Foot/physiology , Models, Anatomic , Muscle, Skeletal/physiology , Prosthesis Design/methods , Walking/physiology , Amputees , Feedback, Physiological , Humans , Muscle, Skeletal/innervation , Tendons/physiology
6.
Article in English | MEDLINE | ID: mdl-19964375

ABSTRACT

A transtibial amputee does not have a functional gastrocnemius muscle, which affects the knee as well as the ankle joint. In this investigation, we developed a transtibial prosthesis comprising an artificial gastrocnemius mechanism as well as a powered ankle-foot device. A pilot study was conducted with a bilateral transtibial amputee walking at a self-selected speed. The trial compared muscle electromyography and metabolic cost data for the amputee while using the active gastrocnemius prosthesis and a conventional Flex-Foot prosthesis. The experimental data showed that the compensation for ankle-foot and gastrocnemius function offered by the active device resulted in a reduced metabolic cost for the amputee participant.


Subject(s)
Amputees/rehabilitation , Artificial Limbs , Tibia/surgery , Ankle Joint/physiology , Foot/physiology , Humans , Prosthesis Design
7.
J Biol Chem ; 284(11): 7149-56, 2009 Mar 13.
Article in English | MEDLINE | ID: mdl-18684712

ABSTRACT

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.


Subject(s)
Activin Receptors, Type I/metabolism , Bone Morphogenetic Protein Receptors, Type I/metabolism , Cell Differentiation , Matrix Metalloproteinases, Secreted/metabolism , Myositis Ossificans/metabolism , Osteoblasts/metabolism , Osteogenesis , Signal Transduction , Smad1 Protein/metabolism , Smad5 Protein/metabolism , Activin Receptors, Type I/genetics , Amino Acid Substitution , Animals , Bone Morphogenetic Protein Receptors, Type I/genetics , Cell Line , Female , Humans , Male , Matrix Metalloproteinases, Secreted/genetics , Mice , Mutation, Missense , Myositis Ossificans/genetics , Myositis Ossificans/pathology , Osteoblasts/pathology , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Smad1 Protein/genetics , Smad5 Protein/genetics , Smad7 Protein/genetics , Smad7 Protein/metabolism
8.
Stem Cells ; 25(3): 628-38, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17110619

ABSTRACT

This study was undertaken to determine whether human oral keratinocyte stem cells characteristically express higher levels of the low-affinity neurotrophin receptor p75 and to elucidate the function of p75 in oral keratinocytes. Examination of their expression patterns and cell-cycling status in vivo showed that p75 was exclusively expressed in the basal cell layer of both the tips of the papillae and the deep rete ridges. These immunostaining patterns suggest a cluster organization; most p75(+) cells did not actively cycle in vivo. Cell sorting showed that cells in the p75(+) subset were smaller and possessed higher in vitro proliferative capacity and clonal growth potential than the p75(-) subset. Clonal analysis revealed that holoclone-type (stem cell compartment), meroclone-type (intermediate compartment), and paraclone-type (transient amplifying cell compartment) cells, previously identified in skin and the ocular surface, were present in human oral mucosal epithelium. Holoclone-type cells showed stronger p75 expression at both the mRNA and protein level than did meroclone- and paraclone-type cells. Among the several neurotrophins, nerve growth factor (NGF) and neurotrophin-3 stimulated p75(+) oral keratinocyte cell proliferation, and only NGF protected them from apoptosis. Our in vivo and in vitro findings indicate that p75 is a potential marker of oral keratinocyte stem/progenitor cells and that some neurotrophin/p75 signaling affects cell growth and survival.


Subject(s)
Keratinocytes/cytology , Receptor, Nerve Growth Factor/physiology , Stem Cells/cytology , Stem Cells/physiology , Apoptosis , Cell Culture Techniques , Cell Cycle , Cell Fractionation , Clone Cells , Colony-Forming Units Assay , Flow Cytometry , Gene Expression Regulation , Humans , Keratinocytes/physiology , Mouth Mucosa/cytology , Mouth Mucosa/physiology , Receptor, Nerve Growth Factor/deficiency , Receptor, Nerve Growth Factor/genetics , Reference Values , Reverse Transcriptase Polymerase Chain Reaction
9.
Chem Commun (Camb) ; (6): 711-2, 2005 Feb 14.
Article in English | MEDLINE | ID: mdl-15685312

ABSTRACT

Treatment of thiacalix[8]arene (3.8H) with KH in THF, followed by recrystallization from methanol, affords an adduct of [K4(3.4H)].8MeOH as a pale yellow crystal (4), which shows highly-extensive coordination that gives rise to a zeolitic structure. An adduct of 4 gives apohost [K4(3.4H)] with the loss of methanol, which can adsorb such gaseous organic guest molecules as methanol and benzene. After binding methanol as the guest molecule, the apohost is converted back to the original structure of 4.

10.
Invest Ophthalmol Vis Sci ; 45(11): 3951-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15505041

ABSTRACT

PURPOSE: Immunohistochemically, all cells in the porcine corneal epithelium, from the superficial to the basal layer, express integrin beta1. Flow cytometric study has shown that they comprise integrin beta1 high-expressing (beta1 2+) and low-expressing (beta1+) populations. This study was undertaken to determine their proliferation characteristics. METHODS: Epithelial cells from porcine corneas were sorted and labeled with anti-integrin beta1 antibody and a fluorescent-dye-conjugated secondary antibody. The fluorescent intensity of labeled cells was analyzed and beta1 2+ and beta1+ cells were cultured in an adhesive-coated culture plate. RESULTS: Flow cytometry demonstrated that the epithelial cells comprised two distinct populations with a similar ratio throughout the cornea. Whereas beta1 2+ cells attached and grew to confluence in the plate, beta1+ attached only transiently to the plate and exhibited minimal growth. CONCLUSIONS: The data indicate that the porcine cornea contains two distinct populations of epithelial cells, one exhibiting high and the other low integrin beta1 expression. The observation that beta1 2+ cells had greater growth potential suggests that they may represent an enriched population of transit-amplifying cells.


Subject(s)
Epithelium, Corneal/cytology , Epithelium, Corneal/metabolism , Integrin beta1/metabolism , Animals , Cell Culture Techniques , Cell Division , Cell Separation , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Stem Cells , Swine
11.
Exp Eye Res ; 79(2): 175-80, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15325564

ABSTRACT

Human beta-defensins (hBDs), which are mainly expressed in epithelial tissues, may contribute to infection-protective mechanisms in the ocular surface. We examined hBD1 and hBD2 expression in the ocular surface by RT-PCR and immunohistochemistry and studied the effects of immunosuppressive agents on their expression in human corneal epithelial cells in vitro. mRNA expression of hBD1 and hBD2 was confirmed in corneal epithelial cells. While the hBD1 peptide was immunohistochemically detected in corneal, limbal, and conjunctival epithelium, the level of expression was stronger in limbal- and conjunctival- than in corneal epithelium. Very weak expression of the hBD2 peptide was detected only in corneal epithelium. After 48-h culture of human corneal epithelial cells in the presence of 10(-5) M dexamethasone or 1 mg l(-1) cyclosporin A, total RNA was extracted and hBD1 and hBD2 mRNA expressions compared using semi-quantitative RT-PCR and introduced amplified fragment length polymorphism (iAFLP) assay. The two methods yielded almost identical results. hBD1 mRNA expression was not changed by dexamethasone but was down-regulated by cyclosporin A. hBD2 mRNA expression was up-regulated by dexamethasone and down-regulated by cyclosporin A. Our findings suggest that hBD1 and hBD2 are regulated by different mechanisms and that hBD1 may contribute to infection-protective mechanisms in the relatively immunosuppressed status induced by dexamethasone.


Subject(s)
Cyclosporine/pharmacology , Dexamethasone/pharmacology , Epithelium, Corneal/drug effects , Immunosuppressive Agents/pharmacology , beta-Defensins/metabolism , Adult , Cells, Cultured , Epithelium, Corneal/metabolism , Gene Expression Regulation/drug effects , Humans , Male , Polymorphism, Genetic , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , beta-Defensins/genetics
12.
Invest Ophthalmol Vis Sci ; 45(6): 1771-4, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15161839

ABSTRACT

PURPOSE: To reexamine whether the alpha5 chain of type IV (alpha5[IV]) collagen, thought to be absent, is in fact present in human amniotic membrane. METHODS: Cryosections of human amniotic membrane obtained at Cesarean section were immunohistochemically examined for the presence of alpha5(IV), with or without inclusion of the denaturing step. Amniotic membrane was digested with collagenase to release the noncollagenous NC1 domain from the alpha-chain. The NC1 domain of alpha5(IV) was then assayed on Western blot analysis. Identical experiments were performed with human corneas and conjunctivae obtained from an American eye bank. RESULTS: The basement membrane of denatured samples of amniotic membrane and cornea stained positive for alpha5(IV). Without the denaturing step, only corneal samples were positive. With or without denaturing, conjunctival epithelium did not stain. Western blot analysis detected NC1 domains of alpha5(IV) in amniotic membrane and corneal samples. CONCLUSIONS: The basement membrane of amniotic membrane resembles that of corneal epithelium but not conjunctiva. Amniotic membrane may be an excellent substrate for corneal epithelial cells.


Subject(s)
Amnion/metabolism , Collagen Type IV/metabolism , Epithelium, Corneal/metabolism , Basement Membrane/metabolism , Blotting, Western , Conjunctiva/metabolism , Female , Fluorescent Antibody Technique, Indirect , Humans
13.
Exp Eye Res ; 78(6): 1137-41, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15109920

ABSTRACT

Rabbit immunoglobulin G (IgG) binds specifically to the human corneal epithelium. We investigated this phenomenon to identify the binding material in the tissue. Sections of human cornea were immunostained with negative-control grade rabbit IgG, F(ab')(2) (the antigen recognition fragment of IgG yielded by pepsin digestion), and Fc fragments. Human corneal epithelium was homogenized in a buffer containing Triton X-100 and the water-insoluble residue was subjected to two-dimensional gel electrophoresis. Western blotting was performed on the gels to detect materials that bound with rabbit IgG Fc fragments. Spots in the gel that bound with the Fc fragments were collected and analysed by peptide mass fingerprinting (PMF). Using an antibody against a binding candidate, keratin 5 (suggested by PMF analysis), we checked the occurrence of this phenomenon. Immunohistochemistry showed that rabbit IgG bound to corneal epithelium via the Fc region but not F(ab')(2). Western blots using rabbit Fc fragments showed that some protein spots in the gel bound to the fragments. All of the binding materials were basic and had molecular weights of approximately 55 kDa. PMF analysis showed that the binding material was keratin 5; all binding materials on the transferred membrane were recognized by an anti-keratin 5 antibody. On corneal sections, anti-keratin 5 produced staining similar to that of rabbit IgG. These findings suggest that rabbit IgG binds to keratin 5 in the human corneal epithelium via the Fc region of the molecule.


Subject(s)
Epithelium, Corneal/immunology , Immunoglobulin Fc Fragments/metabolism , Immunoglobulin G/metabolism , Keratins/metabolism , Animals , Electrophoresis, Gel, Two-Dimensional , Epithelium, Corneal/metabolism , Humans , In Vitro Techniques , Keratin-5 , Peptide Mapping , Protein Binding , Rabbits
14.
Invest Ophthalmol Vis Sci ; 44(1): 106-16, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12506062

ABSTRACT

PURPOSE: To determine the feasibility of using human amniotic membrane (AM) as a substrate for culturing oral epithelial cells and to investigate the possibility of using autologous cultivated oral epithelial cells in ocular surface reconstruction. METHODS: An ocular surface injury was created in one eye of each of eight adult albino rabbits by a lamellar keratectomy, and a conjunctival excision was performed, including and extending 5 mm outside the limbus. Oral mucosal biopsy specimens were obtained from these eight adult albino rabbits and cultivated for 3 weeks on a denuded AM carrier. The cultivated epithelium was examined by electron microscopy (EM) and immunohistochemically labeled for several keratins. At 3 to 4 weeks after the ocular surface injury, the conjunctivalized corneal surfaces of the eight rabbits were surgically reconstructed by transplanting the autologous cultivated oral epithelial cells on the AM carrier. RESULTS: The cultivated oral epithelial sheet had four to five layers of stratified, well-differentiated cells. EM revealed that the epithelial cells were very similar in appearance to those of normal corneal epithelium, had numerous desmosomal junctions, and were attached to a basement membrane with hemidesmosomes. Immunohistochemistry confirmed the presence of the keratin pair 4 and 13 and keratin-3 in the cultivated oral epithelial cells. Corneas that were grafted with the cultivated oral epithelial cells on an AM carrier were clear and were all epithelialized 10 days after surgery. CONCLUSIONS: Cultures of oral epithelial cells can be generated to confluence on AM expanded ex vivo from biopsy-derived oral mucosal tissue. Autologous transplantation was performed with these cultivated oral epithelial cells onto the ocular surfaces of keratectomized rabbit eyes. Autologous transplantation of cultivated oral epithelium is a feasible method for ocular surface reconstruction. The long-term outcome of such transplantation is not yet clear, and its feasibility in clinical use should be evaluated further.


Subject(s)
Amnion , Cell Culture Techniques/methods , Corneal Injuries , Epithelial Cells/transplantation , Eye Injuries/surgery , Mouth Mucosa/cytology , Animals , Cell Division , Disease Models, Animal , Epithelial Cells/metabolism , Epithelial Cells/ultrastructure , Feasibility Studies , Fluorescent Antibody Technique, Indirect , Humans , Keratins/metabolism , Rabbits , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...